Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19

Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19

Background: Castleman disease (CD) is a rare lymphoproliferative disorder with various subtypes, including the HHV-8-negative/idiopathic multicentric CD (iMCD). The diagnosis of iMCD remains challenging due to its non-specific presentation, in the form of generalised lymphadenopathies and inflammati...

Full description

Bibliographic Details
Main Authors: Helbies Bedier, Stéphane Isnard, Chelsea Maedler-Kron, Jean-Pierre Routy
Format: Article
Language:English
Published: SMC MEDIA SRL 2023-11-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
lymphoproliferative disorders
multicentric castleman disease
siltuximab
il-6
covid-19
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/4098

Internet

https://www.ejcrim.com/index.php/EJCRIM/article/view/4098

Similar Items